Sekisui Diagnostics has entered into a strategic partnership with Qualigen to collaborate on the current and future business opportunities and become the commercial partner for the Qualigen FastPack IP System in the US and international markets.
The Qualigen-developed FastPack IP System is a fully automated blood analyser which generates rapid, quantitative immunoassay results with the push of a button for important biomarkers in the areas of cancer, metabolic disorders, hormone regulation and pregnancy management.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The system caters to the requirements of the physician office laboratories (POLs) to get a quick and an easy test result coupled with a clinical value.
The FastPack IP System is characterised by its one touch operation; an all inclusive reagent pack; offering lab quality precision and a quick result with no specialised training required.
Sekisui Diagnostics president and COO Robert Schruender said: "Sekisui Diagnostics is delighted to announce our new relationship with Qualigen which will add to our existing rapid test portfolio in POL markets.
"This system is highly compatible with our business channels and relationship with distributors, especially McKesson.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"It also offers the potential to strengthen our portfolio in the mid-to-long term."
Sekisui Diagnostics is focused on providing new medical diagnostics to physicians and laboratories through a global commercial network.
Its product lines include clinical chemistry and coagulation systems, reagents, infectious disease testing and rapid test kits, as well as enzymes and specialty bio-chemicals.
Image: Qualigen’s FastPack IP System. Photo: courtesy of Sekisui Diagnostics.
